Fabry Disease disease mechanism in adults
Fabry disease is a rare genetic disorder classified as a lysosomal storage disorder, resulting from a deficiency of the enzyme alpha-galactosidase A. This enzyme plays a critical role in breaking down a fatty substance called globotriaosylceramide (Gb3 or GL-3). When the enzyme is deficient or dysfunctional, Gb3 accumulates within various cell types throughout the body, leading to widespread tissue and organ damage. While Fabry disease is often diagnosed in childhood, many cases remain undetected until adulthood when symptoms become more pronounced or complications arise.
The underlying disease mechanism in adults begins with the genetic mutation in the GLA gene, which encodes the alpha-galactosidase A enzyme. This mutation results in reduced or absent enzyme activity, causing Gb3 to build up particularly in the vascular endothelium—the lining of blood vessels—as well as in smooth muscle cells, cardiac tissues, kidneys, and the nervous system. The accumulation of Gb3 within endothelial cells causes structural disruptions and impairs normal vessel function. This impairment leads to a cascade of pathological events, including vascular inflammation, increased vessel permeability, and eventual tissue ischemia.
One of the hallmark features of Fabry disease is its impact on the vascular system. The storage of Gb3 within endothelial cells causes cellular hypertrophy and dysfunction, leading to vascular narrowing and increased susceptibility to blood flow disturbances. Over time, these vascular issues can precipitate a variety of symptoms such as acroparesthesias—burning or tingling sensations in the extremities—angiokeratomas (small, dark red skin lesions), and episodes of pain often triggered by heat or exercise. These symptoms reflect the nerve damage and vascular pathology caused by Gb3 deposits.
As the disease progresses, Gb3 accumulation can cause significant organ damage. In the kidneys, it leads to progressive renal fibrosis and proteinuria, often culminating in chronic kidney disease. Cardiac involvement is common and includes left ventricular hypertrophy, arrhythmias, and in some cases, heart failure. The nervous system may also be affected, resulting in small fiber neuropathy, which causes pain, numbness, and decreased temperature sensation. The progressive nature of Gb3 accumulation means that without intervention, organ function deteriorates over time, increasing morbidity and mortality in untreated adults.
The disease mechanism in adults also involves secondary cellular processes such as oxidative stress and inflammation, which further exacerbate tissue damage. Gb3 deposits interfere with cellular signaling pathways, induce apoptosis (cell death), and promote a pro-inflammatory environment. These processes contribute to the chronic progression of the disease and complicate management strategies.
Understanding the disease mechanism in adults highlights the importance of early diagnosis and treatment. Enzyme replacement therapy (ERT) and chaperone therapy aim to reduce Gb3 accumulation, decrease vascular and organ damage, and improve quality of life. However, the effectiveness of these treatments depends on timely intervention before irreversible organ damage occurs.
In summary, Fabry disease’s pathophysiology in adults centers around the enzymatic deficiency leading to Gb3 buildup within vascular and organ tissues. This accumulation causes cellular and tissue dysfunction that manifests as pain, skin lesions, and progressive organ failure, emphasizing the need for early detection and targeted therapy to mitigate long-term complications.